Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122 · cited 1×
“Nitric oxide (NO) generation is therefore an essential component of the response pattern to angiogenic growth factors [15]; thus VEGF blockade and NO inhibition could result in several common abnormalities.”
BackgroundEndothelial Function and Dysfunction: Testing and Clinical Relevance
Deanfield, J. E., Halcox, J. P., & Rabelink, T. J. (2007) · Circulation · doi:10.1161/circulationaha.106.652859 · Cited by 2,710
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Miller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306
The role of nitric oxide in tumour progression
Fukumura, D., Kashiwagi, S., & Jain, R. K. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1910 · Cited by 1,259
Nitric oxide synthase modulates angiogenesis in response to tissue ischemia.
Murohara, T., Asahara, T., Silver, M., Bauters, C., Masuda, H., Kalka, C., Kearney, M., Chen, D., Symes, J. F., Fishman, M. C., et al. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1560 · Cited by 1,200
Papapetropoulos, A., García-Cardeña, G., Madri, J. A., & Sessa, W. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119868 · Cited by 1,191
The VIVA Trial: Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis
Henry, T. D., Annex, B. H., McKendall, G. R., Azrin, M. A., Lopez, J. J., Giordano, F. J., Shah, P. K., Willerson, J. T., Benza, R. L., Berman, D. S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000061911.47710.8a · Cited by 1,025
Fukumura, D., Gohongi, T., Kadambi, A., Izumi, Y., Ang, J., Yun, C.-O., Buerk, D. G., Huang, P. L., & Jain, R. K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041359198 · Cited by 1,020
Cited by
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., Criscitiello, C., Goldhirsch, A., Cipolla, C., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds293 · Cited by 865
Diabetes, cardiovascular disease and the microcirculation
Strain, W. D., & Paldánius, P. M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0703-2 · Cited by 609
Linking endothelial dysfunction with endothelial cell activation
Liao, J. K. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66843 · Cited by 456
Maitland, M. L., Bakris, G. L., Black, H. R., Chen, H. X., Durand, J.-B., Elliott, W. J., Ivy, S. P., Leier, C. V., Lindenfeld, J., Liu, G., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq091 · Cited by 410
Immune cells control skin lymphatic electrolyte homeostasis and blood pressure
Wiig, H., Schröder, A., Neuhofer, W., Jantsch, J., Kopp, C., Karlsen, T. V., Boschmann, M., Goss, J., Bry, M., Rakova, N., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60113 · Cited by 402
Secondary arterial hypertension: when, who, and how to screen?
Rimoldi, S. F., Scherrer, U., & Messerli, F. H. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht534 · Cited by 393
“Mechanisms involved in the development of hypertension include decrease in nitric oxide bioavailability, rarefaction of the microvascular bed, and activation of endothelin-1 synthesis, one of the most potent vasoconstrictors.(26,27) With Bevacizumab (Avastin), the first drug of this class introduced in 2004 for the tr…”
BackgroundManagement of hypertension in angiogenesis inhibitor-treated patients
Izzedine, H., Ederhy, S., Goldwasser, F., Soria, J. C., Milano, G., Cohen, A., Khayat, D., & Spano, J. P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn713 · Cited by 347
Pandey, A. K., Singhi, E. K., Arroyo, J. P., Ikizler, T. A., Gould, E. R., Brown, J., Beckman, J. A., Harrison, D. G., & Moslehi, J. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10271 · Cited by 338
Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., Hendrikse, N. H., Eriksson, J., Windhorst, A. D., Postmus, P. E., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.023 · Cited by 337
“As inhibitors of VEGF/VEGFR-2 signaling may induce so-called rarefaction (Mourad et al., 2008), that is, a reduction in the number of arterioles or capillaries within vascular beds of various tissues (e.”
BackgroundStrategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Scartozzi, M., Galizia, E., Chiorrini, S., Giampieri, R., Berardi, R., Pierantoni, C., & Cascinu, S. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn637 · Cited by 327
Zhu, X., Stergiopoulos, K., & Wu, S. (2009) · Acta Oncologica · doi:10.1080/02841860802314720 · Cited by 312
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Jubb, A. M., & Harris, A. L. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70232-1 · Cited by 295
Lima, A. B. C., Macedo, L. T., & Sasse, A. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022681 · Cited by 92
Plummer, C., Michael, A., Shaikh, G., Stewart, M., Buckley, L., Miles, T., Ograbek, A., & McCormack, T. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0481-y · Cited by 52
Metadata
- Authors
- Mourad, J.-J., des Guetz, G., Debbabi, H., & Levy, B. I.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2008-05
- Volume
- 19
- Issue
- 5
- Pages
- 927-934
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2164363535
- Cited by
- 306
- References
- 38
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.